Page 370 - Binder2

• And fragile in the face of supply shocks,
infrastructure gaps, and global disparities.

The problem isn’t just the drug—it’s the scaffolding we’ve
built around it.

A System Optimized for Complexity, Not Humanity

Today’s biologic drugs are often:

• Injected or infused.
• Refrigerated at every step of the supply chain.
• Administered under medical supervision.
• Reimbursed through complex payer pathways.
• Delivered in environments designed to minimize
liability, not maximize dignity.

This system serves the molecule—but rarely the patient.

It’s a structure built around:

• Procedure codes.
• Infusion suites.
• Corporate margins.
• Risk aversion.

And as a result, it’s a system that works exceptionally well
for a small subset of people—and poorly for everyone
else.

368